ABSTRACT

Background: Atypical adenomatous hyperplasia (AAH) is a small, glandular proliferation that has histological similarities to Gleason grade 1 and 2 prostatic adenocarcinoma (PACG 1, 2). There are no distinct histomorphological criteria distinguishing these two lesions from each other and other small glandular proliferations. It is necessary to define histological criteria, as treatment approaches are different for these lesions.

Objectives: This study’s aim was to evaluate the differences in the secretory properties of AAH and PACG 1, 2. We searched for intraluminal crystalloids, corpora amylacea, mucin, and eosinophilic material.

Subjects and Methods: 105 totally embedded radical prostatectomy specimens containing 11 AAH (22 foci) and 15 PACG 1, 2 (22 foci) lesions were evaluated. Basal cell specific antikeratin was applied. We accepted that PACG 1, 2 lesions do not contain basal cells, and we grouped lesions as AAH and PACG 1, 2 based on this opinion. The luminal contents were evaluated by PASAB2, 5 and PTAH.

Results: We found differences between the AAH and PACG 1, 2 lesions for some parameters, including crystalloids, corpora amylacea, and mucin. We found similar properties between the two lesions for eosinophilic material.

Conclusion: In a difficult case, evaluation of the luminal content features may be helpful, but the diagnosis must be supported by immunohistochemistry.

Key Words: Adenosis, Small Glandular Proliferations, Low-Grade Cancer, Prostate, Crystalloids

Correspondence: Ahmet Midi, Pathology Laboratory, Maltepe University, Atatürk cad. Çam sok. No 3, Maltepe, Istanbul, 34882, ahmetmidi@yahoo.com

ABSTRACT

Intractable dysuria several months after Greenlight™ laser transurethral resection of prostate (PVP) is a well-known occurrence that may affect some men. We present a patient who suffered dysuria for four months after Greenlight™ vaporization but had prompt resolution after undergoing holmium laser ablation of the prostatic fossa. A possible explanation is discussed.

KEYWORDS: Benign Prostatic Hyperplasia, Laser, Dysuria

CORRESPONDENCE: Steve Y Chung, 3068 E. 1825th Road, Ottawa, IL, 61350, chungsy@gmail.com

Dear Colleagues,

I would like to announce the launch of the UroToday International Journal® (UIJ) (http://www.urotodayinternationaljournal.com), a new online, peer-reviewed, fast-tracked urology and urologic oncology publication. UIJ focuses specifically on the professional global urology and urologic oncology community. It will elevate the access to relevant urology and oncology science to professionals around the world. UIJ will make the scientific information available to a much wider audience than that reached by other journals, including potential readers who do not have access to a research library that can afford to pay for journal subscriptions. There is no charge to register, submit or publish an article in the UIJ. Additionally there are no charges for color figures. There is no other urology journal offering this unique approach to achieve peer-review publication.

UIJ reaches currently over 55,000 professionals in urology. UIJ will open for general submission of manuscripts on May 31st, 2008 for the July issue.

All manuscripts will be subject to rigorous peer-review. All accepted articles will be given Digital Object Identifier (DOI) numbers so that they can be retrieved and indexed by Pubmed as soon as the pending application from UroToday International Journal has been accepted.

The UroToday International Journal® has an international editorial board headed by myself, Professor at the Institute for Regenerative Medicine at Wake Forest University. The Section/Associate Editors are; Christopher P. Evans, Christian Gratzke and Yasuhiko Igawa. Christopher P. Evans MD, FACS is the Chair of the Department of Urology and Professor & Chairman of Urologic Surgical Oncology University of California, Davis, School of Medicine. Christian Gratzke is an Urologist in the Department of Urology, at the University of Munich in Germany and Yasuhiko Igawa, MD, PhD, is Professor in the Department of Urology at Shinshu University School of Medicine, Japan.Gina B. Carithers is the Publisher of both the UroToday International Journal® and www.urotoday.com. The Managing Editor is Tracy Ireland.

Kind regards,
Karl-Erik Andersson, MD, PhD

Editor-In-Chief

ABSTRACT

Introduction: Stress urinary incontinence (SUI) is the involuntary leakage of urine during periods of increased abdominal pressure (e.g., coughing, running or lifting). It is caused by an incompetent urethral sphincter which may arise as a consequence of damage to the pelvic floor muscles sustained during pregnancy and childbirth. Pharmacological therapy includes the off-label use of sympathomimetic medication (alpha-adrenergic agonists), to enhance urethral tone and alleviate symptoms, however their associated cardiovascular side effects (e.g. hypertension) limits their utility. PSD503 (Plethora Solutions Ltd, London, UK) is a controlled dose topical gel, which contains the alpha-adrenergic agonist phenylephrine (20% w/w). It has been developed as a locally administered treatment for SUI, to increase urethral tone and provide symptomatic relief, in the absence of systemic side effects.

Background

Obesity is an established and modifiable risk factor for urinary incontinence (UI) but conclusive evidence for a beneficial effect of weight loss on UI is lacking.